A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)-- pegaptanib sodium (Macugen)-- reduced vision loss in 70% of clinical trial patients.
---
Gragoudas, Evangelos S., Anthony P. Adamis, Emmett T. Cunningham, Matthew Feinsod, and David R. Guyer. "Pegaptanib for Neovascular Age-Related Macular Degeneration". NEJM. Vol. 351, No. 27, pp. 2805-16. [ Permalink ] |